Inovio Pharmaceuticals Presents Immuno-Oncology Advancements … – Nasdaq
Weekly Register |
Inovio Pharmaceuticals Presents Immuno-Oncology Advancements …
Nasdaq PLYMOUTH MEETING, Pa., Nov. 10, 2017– Inovio Pharmaceuticals, Inc. today announced that two of its cancer immunotherapies demonstrated. Inovio Pharmaceuticals to Participate In Upcoming Investment ConferencesMarkets Insider What You Need to Know From Inovio Pharmaceuticals’ Q3 UpdateMadison.com Inovio Pharmaceuticals’ (INO) CEO Dr. J. Joseph Kim on Q3 2017 Results – Earnings Call TranscriptSeeking Alpha StockNewsTimes all 65 news articles » |
Xconomy |
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up
Xconomy The Cambridge, MA, company, seeded last year by a subsidiary of the nonprofit group CureDuchenne, will use a $40 million Series A round led by The Column Group to advance a Duchenne treatment using the gene editing technology CRISPR-Cas9. |
|
Internship ‘bridges’ students to professional stem cell researchers
Daily Aztec The internship program, called the Bridges to Stem Cells Research Internship Program, provides students with the chance to work in a professional lab setting and complete extensive, year-long research on stem cells, said Susan Kaiser, the program’s … |
|
Re-engineered T Cells Show Promise in Fighting HIV
MD Magazine The proteins, called chimeric antigen receptors (CARs), are designed to fight specific diseases (in this case, HIV). The technique involves taking a patient’s blood sample and then re-engineering the T cells in a lab to express disease-specific CARs … |
|
ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and …
Business Wire (press release) DUBLIN & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual … |